The SIX1 Gene Deafness Autosomal Dominant Type 23 Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the SIX1 gene, which are linked to Autosomal Dominant Deafness Type 23 (DFNA23). This condition is characterized by varying degrees of hearing loss, often identified in early childhood or adolescence. The SIX1 gene plays a crucial role in the development of the inner ear, and mutations in this gene can disrupt normal hearing capabilities.
Conducted at DNA Labs UAE, this genetic test is pivotal for families with a history of hearing loss, providing them with crucial information regarding the genetic underpinnings of their condition. The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed for specific genetic alterations associated with DFNA23.
The cost of the SIX1 Gene Deafness Autosomal Dominant Type 23 Genetic Test is 4400 AED. This price reflects the comprehensive nature of the test, including the collection of the sample, the genetic analysis, and the provision of a detailed report that explains the results. This report is instrumental for affected individuals and their families in understanding their condition and planning for any necessary medical or supportive interventions.
DNA Labs UAE, known for its state-of-the-art facilities and highly qualified staff, ensures that the test is conducted with the highest standards of accuracy and confidentiality. The results from this test can significantly impact the management and treatment of hearing loss, offering a pathway to genetic counseling and personalized care strategies for affected individuals and their families.
The SLC17A8 gene is implicated in a form of hearing loss known as Deafness Autosomal Dominant Type 25 (DFNA25). This condition is characterized by a variation in the SLC17A8 gene, which plays a critical role in the function of the inner ear, affecting the ability to hear. Genetic testing for mutations in the SLC17A8 gene is crucial for diagnosing this specific type of hereditary hearing loss, enabling individuals and families to understand their condition better and make informed decisions regarding their health and management options.
At DNA Labs UAE, a specialized genetic test is available to identify mutations in the SLC17A8 gene associated with Deafness Autosomal Dominant Type 25. The test is a comprehensive analysis designed to detect the specific genetic alterations that lead to this condition, providing a definitive diagnosis for affected individuals or those at risk.
The cost of the SLC17A8 gene deafness autosomal dominant type 25 genetic test at DNA Labs UAE is 4400 AED. This investment covers the expenses of the genetic analysis, including the collection of a DNA sample, typically through a blood draw or cheek swab, the laboratory processing, and the expert interpretation of the results. Following the test, individuals receive a detailed report that explains the findings and their implications for hearing health, with recommendations for follow-up care or interventions as needed. This genetic test is a valuable tool for those with a family history of hearing loss or early signs of hearing impairment, offering insights that can lead to early intervention and support.
The GRHL2 gene, associated with Deafness Autosomal Dominant Type 28 (DFNA28), plays a critical role in the development and maintenance of the ear's structure and function. Mutations in this gene can lead to hearing loss that is passed down through families in a pattern known as autosomal dominant inheritance. This means that only one copy of the altered gene in each cell is sufficient to cause the disorder, and it can be inherited from just one affected parent.
To diagnose this specific type of genetic hearing loss, a genetic test targeting the GRHL2 gene can be conducted. This test involves analyzing the DNA to look for mutations in the GRHL2 gene that are known to cause DFNA28. It is a crucial step for affected families to understand their genetic background, potential risks for future generations, and to explore suitable management or treatment options.
In the UAE, this specific genetic test for the GRHL2 gene can be performed at DNA Labs UAE, a reputable facility known for its comprehensive range of genetic testing services. The cost for this test is 4400 AED, which translates to approximately 1197 USD. The price reflects the sophisticated technology and expertise required to accurately identify mutations in the GRHL2 gene and provide a reliable diagnosis. Individuals considering this test should consult with a healthcare provider or a genetic counselor to discuss the implications of the results and the best course of action based on their personal and family medical history.
The "KCNQ4 Gene Deafness Autosomal Dominant Type 2A Genetic Test" is a specialized diagnostic tool designed to identify mutations in the KCNQ4 gene, which are known to cause Autosomal Dominant Non-Syndromic Hearing Loss (ADNSHL) type 2A. This form of hearing loss is characterized by its inheritance pattern, where only one copy of the mutated gene from an affected parent can lead to the condition in the offspring, showcasing a dominant inheritance pattern.
The KCNQ4 gene plays a critical role in the function of inner ear cells by contributing to the proper creation of potassium channels. These channels are essential for the conversion of sound waves into electrical signals that the brain can interpret as sound. Mutations in the KCNQ4 gene disrupt this process, leading to progressive hearing loss.
The test, offered by DNA Labs UAE, utilizes advanced genetic sequencing technologies to scrutinize the KCNQ4 gene for any abnormalities that might be responsible for hearing loss. By providing a precise genetic diagnosis, the test enables targeted management and counseling for affected individuals and their families. It is particularly beneficial for early detection, allowing for timely intervention strategies that can significantly improve the quality of life for those with the condition.
Priced at 4400 AED, this genetic test represents a crucial investment for families with a history of hearing loss, offering them valuable insights into their genetic makeup and the potential for hereditary hearing loss conditions. Conducted in the state-of-the-art facilities of DNA Labs UAE, the test adheres to high standards of accuracy, confidentiality, and ethical considerations, ensuring reliable results for patients seeking clarity about their genetic health.
The TMC1 Gene Deafness Autosomal Dominant Type 36 Genetic Test is a specialized diagnostic examination offered by DNA Labs UAE, designed to detect mutations in the TMC1 gene, which are associated with Autosomal Dominant Non-Syndromic Hearing Loss (ADNSHL) type 36. This condition is characterized by varying degrees of hearing impairment that can present from birth or develop later in life, primarily affecting the ability to perceive sound due to genetic abnormalities.
This test is crucial for individuals with a family history of hearing loss or those showing symptoms of auditory impairment, as it helps in confirming the diagnosis, understanding the risk of transmission to offspring, and aiding in the management and treatment planning of the condition. By analyzing a sample of the patient's DNA, the test identifies specific mutations in the TMC1 gene that are linked to this form of hearing loss, providing valuable genetic insights.
The cost of the TMC1 Gene Deafness Autosomal Dominant Type 36 Genetic Test at DNA Labs UAE is 4400 AED. The price reflects the comprehensive nature of the genetic analysis, the expertise required to interpret the results, and the significant impact the findings can have on the patient's treatment and lifestyle adjustments. Patients considering this test are advised to consult with a healthcare provider or a genetic counselor to understand its implications fully and how the results may influence their health management strategies.
The "GJB2 Gene Deafness Autosomal Dominant Type 3A Genetic Test" is a specialized diagnostic tool designed to identify mutations in the GJB2 gene, which are linked to Autosomal Dominant Deafness Type 3A. This condition is characterized by varying degrees of hearing loss that is passed down through families in an autosomal dominant pattern, meaning only one copy of the altered gene is necessary for the trait to be expressed. The GJB2 gene plays a crucial role in the function of cochlear hair cells and the potassium recycling pathway in the inner ear, which are essential for normal hearing.
Conducted at DNA Labs UAE, a leading facility in genetic testing, this test is priced at 4400 AED. It involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed for specific genetic mutations associated with this form of deafness. The results can provide valuable information for affected individuals and their families, including the confirmation of a genetic diagnosis, understanding the risk of passing the condition to offspring, and guiding decisions about management and treatment options. As with any genetic test, counseling before and after the test is recommended to ensure individuals fully understand the implications of the results.
The MYH14 gene, associated with Deafness Autosomal Dominant Type 4, plays a crucial role in the development and function of the auditory system. Mutations in this gene can lead to hearing impairment, making it a significant focus for genetic testing in individuals experiencing hearing loss with a suspected genetic basis.
The genetic test for MYH14-related deafness is a comprehensive analysis designed to detect mutations within the MYH14 gene that are known to cause Autosomal Dominant Non-Syndromic Hearing Loss (ADNSHL). This form of hearing loss is characterized by its inheritance pattern, where a single copy of the altered gene in each cell is sufficient to cause the condition, and it typically does not affect other body systems.
At DNA Labs UAE, the test for MYH14 gene-related deafness is offered at a cost of 4400 AED. The process involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory using advanced genetic sequencing technologies. This test is not only crucial for diagnosing affected individuals but also for understanding the risk of passing the condition to future generations, thereby aiding in informed family planning decisions.
Individuals who have a family history of hearing loss or have been diagnosed with hearing impairment without a known cause are potential candidates for this test. It provides a definitive diagnosis, enabling healthcare providers to offer tailored advice and management strategies for those affected by hearing loss associated with the MYH14 gene.
The TAT Gene Tyrosinemia Type 2 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to detect mutations in the TAT gene, which are responsible for Tyrosinemia type 2, a rare metabolic disorder. This condition is characterized by elevated levels of tyrosine in the blood, leading to issues such as skin lesions, eye problems, and, in some cases, intellectual disability. The test, priced at 4400 AED, involves analyzing the patient's DNA to identify any genetic alterations in the TAT gene, providing crucial information for accurate diagnosis and enabling targeted treatment approaches. By identifying the specific mutations causing Tyrosinemia type 2, healthcare providers can offer personalized management plans to mitigate the symptoms and improve the quality of life for affected individuals.
The HPD Gene Tyrosinemia Type 3 Genetic Test is a specialized diagnostic procedure designed to detect mutations in the HPD gene, which are associated with Tyrosinemia type 3, a rare metabolic disorder. This condition results from the body's inability to effectively break down the amino acid tyrosine, leading to various health issues, including intellectual disabilities, seizures, and liver problems. Early detection through this genetic test can enable timely intervention and management of the condition, potentially mitigating severe outcomes. The test is available at DNA Labs UAE, a leading facility in genetic diagnostics, offering the test at a cost of 4400 AED. This test is crucial for individuals with a family history of Tyrosinemia or those showing symptoms related to the disorder, providing them with essential insights into their genetic health.
The ECM1 gene Urbach-Wiethe disease genetic test is a specialized diagnostic tool used to identify mutations in the ECM1 gene, which are associated with Urbach-Wiethe disease (UWD), a rare genetic disorder. This condition is characterized by a variety of symptoms, including skin thickening, hoarseness of voice, and, in some cases, neurological issues due to calcium deposits in the brain. The ECM1 gene plays a critical role in skin integrity and structure, and mutations in this gene can lead to the hallmark features of UWD.
The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in a laboratory to identify any genetic abnormalities in the ECM1 gene. This genetic test is crucial for the accurate diagnosis of Urbach-Wiethe disease, enabling healthcare providers to offer appropriate management and treatment options for affected individuals.
The ECM1 gene Urbach-Wiethe disease genetic test is available at DNA Labs UAE, a leading provider of genetic testing services in the United Arab Emirates. The cost of the test is 4400 AED, reflecting the specialized nature of the testing and the expertise required to interpret the results. By offering this test, DNA Labs UAE provides an essential service for patients and families affected by Urbach-Wiethe disease, facilitating early diagnosis and intervention for this rare genetic condition.
